95330-29-3

Upstream product

• 95330-43-1 3-methoxy-2,N-dimethyl-N-(t-butyl)benzamide 
• 24487-91-0 3-methoxy-2-methylbenzoyl chloride 
• 74-89-5 methylamine 
• 55289-06-0 3-methoxy-2-methylbenzoic acid 

Downstream Products

• 95330-35-1 (E)-methyl 3-methoxy-2-pent-1-enylbenzoate 
• 95330-39-5 (E)-3-methoxy-2-pent-1-enylbenzyl alcohol 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

Isochromanone-based urotensin-II receptor agonists

A series of analogues of the selective non-peptide urotensin II (UII) receptor agonist 3-(4-chlorophenyl)-3-(2-dimethylaminoethyl)-isochroman-1-one (AC-7954, 1) was synthesized and evaluated for UII agonist activity using a functional cell-based assay. The introduction of a methyl group in the 4-position resulted in a complete loss of activity, whereas substituents in the aromatic rings were beneficial. Sterically demanding amino groups were also detrimental to the activity. Several potent agonists were identified, six compounds being equally or more potent than 1. The most potent compound in the series was the 6,7-dimethyl analogue of 1 (16, pEC50 6.87). The racemate of 16 was resolved into the pure enantiomers using preparative straight phase HPLC. It was shown that the potency resides in the (+)-enantiomer (pEC50 7.11). The synthesized compounds seem to be selective for the UII receptor as no activities were observed at the closely related SSTR3 and 5 receptors.

UROTENSIN II RECEPTOR MODULATORS

Disclosed are compounds of Formula I, or salts or prodrugs thereof, complexed with a human urotensin II receptor as defined herein. Also disclosed are compounds of Formula II, or salts or prodrugs thereof, as defined herein. Also disclosed are methods of modulating the activity of a urotensin II receptor using a compound of Formula I, or a compound of Formula II, or salts or prodrugs thereof. In addition, methods of treating diseases related to the activity of urotensin II receptors are disclosed.

An Investigation into the Formation of Benzo- and Naphtho-pyrans by Cyclisation of ortho-Alkenyl(hydroxyalkyl)benzenes using either Cerium(IV) Ammonium Nitrate or Potassium t-Butoxide in Dimethylformamide

A series of ortho-alkenylbenzyl alcohols carrying methoxy substituents at appropriate positions on the aromatic ring have been synthesised.Each of these compounds has been treated separately with each of the title reagents.